Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries.

about

Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries.

Item

http://www.wikidata.org/entity/Q55135908

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Delay and inequalities in the ...... case of two Nordic countries.

@en

Delay and inequalities in the ...... case of two Nordic countries.

@nl

type

Item

label

Delay and inequalities in the ...... case of two Nordic countries.

@en

Delay and inequalities in the ...... case of two Nordic countries.

@nl

prefLabel

Delay and inequalities in the ...... case of two Nordic countries.

@en

Delay and inequalities in the ...... case of two Nordic countries.

@nl

P1476

Delay and inequalities in the ...... case of two Nordic countries.

@en

P2093

Carl Magnus Sköld

http://www.w3.org/2001/XMLSchema#string

Lisa Carlson

http://www.w3.org/2001/XMLSchema#string

Marjukka Myllärniemi

http://www.w3.org/2001/XMLSchema#string

Nicola Murgia

http://www.w3.org/2001/XMLSchema#string

Riitta Kaarteenaho

http://www.w3.org/2001/XMLSchema#string

P2860

Population substructure in Finland and Sweden revealed by the use of spatial coordinates and a small number of unlinked autosomal SNPs

Genome-wide analysis of single nucleotide polymorphisms uncovers population structure in Northern Europe

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis

An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management

Re-evaluation of diagnostic parameters is crucial for obtaining accurate data on idiopathic pulmonary fibrosis.

First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value.

Reference values for lung function tests in men: regression equations with smoking variables.

Reference values for lung function tests in females. Regression equations with smoking variables.

End-of-life care of patients with idiopathic pulmonary fibrosis.

P2888

s40248-018-0126-7

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S40248-018-0126-7

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Giovanni Ferrara

Ida Pesonen

P577

2018-05-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1103894385

http://www.w3.org/2001/XMLSchema#string

P698

29785264

http://www.w3.org/2001/XMLSchema#string

P921

pulmonary fibrosis

P932

5950183

http://www.w3.org/2001/XMLSchema#string